EpiBiologics launched in 2023 with a $50 million series A, having been founded to take forward the work of renowned antibody ...

The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that ...

Krystal Biotech (NASDAQ:KRYS) said it has generated positive interim clinical results for its inhaled cystic fibrosis (CF) ...

The team brings a strong balance of scientific and commercial expertise, has built a unique data foundation with a ...

Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech’s preclinical blood cancer program into its ...

Earlier this week, Krystal Biotech reported positive interim data from the highest-dose cohort of its Phase 1 CORAL-1 trial, ...

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...

The companies Kymera Therapeutics, Immunovant, and Dyne Therapeutics bagged the biggest biotech funding rounds overall in ...

Summit Therapeutics has generated plenty of buzz in the biotech industry over the past two years. That's because the ...

VERONA, Italy--(BUSINESS WIRE)--Sibylla Biotech today announced the successful close of its €23 million Series A financing round to fund the further development of its Pharmacological Protein ...

Kymera Therapeutics, a preclinical biotech developing small molecule protein degrader therapies for immunology-inflammation and oncology, filed on Friday with the SEC to raise up to $100 million in an ...